Literature DB >> 25855003

Inflammatory bowel disease.

Morten H Vatn1, Arne K Sandvik.   

Abstract

Scandinavian researchers have contributed to the present understanding of inflammatory bowel disease (IBD). Important epidemiological data and family risk factors have been reported from all the Nordic countries, original twin studies mainly from Denmark and Sweden, and relationships to cancer and surgery mostly from Sweden. In collaboration with the industry, development of medical compounds was for a long time in the front line of international research, and the Scandinavian countries participated in the clinical breakthrough of biologic treatment. At present, many Nordic centers are working in the forefront of IBD research. An increasing number of young investigators have entered the scene along with the extended distribution of University clinics and research laboratories in these countries. This presentation of IBD gives a brief overview in the fields of clinical epidemiology and molecular biology. Many areas are covered by International collaborations with partners from Nordic centers. IBD was a topic focused by the founders of Scandinavian Journal of Gastroenterology. After 50 years one may state that the journal's history reflects important pieces of scientific knowledge within these diseases. The early scope of Johannes Myren for IBD was shown through his work in the original World Association of Gastroenterology (OMG), and after 50 years we can clearly support the view that global perspectives in IBD are increasingly important.

Entities:  

Keywords:  Crohn’s disease; clinical; environment; epidemiology; genetics; inflammatory bowel diseases; molecular biology; treatment; ulcerative colitis

Mesh:

Year:  2015        PMID: 25855003     DOI: 10.3109/00365521.2015.1033000

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.

Authors:  Doha Anka Idrissi; Nezha Senhaji; Asmae Aouiss; Loubna Khalki; Youssef Tijani; Nabil Zaid; Fatima Zahra Marhoume; Abdallah Naya; Mounia Oudghiri; Mostafa Kabine; Younes Zaid
Journal:  Arch Pharm Res       Date:  2021-01-04       Impact factor: 4.946

2.  Analysis of Phenotypic Variables and Differentiation Between Untypical Crohn's Disease and Untypical Intestinal Tuberculosis.

Authors:  Yu Meng; Ying Li; Rong Hao; Xiaojun Li; Fanggen Lu
Journal:  Dig Dis Sci       Date:  2019-02-06       Impact factor: 3.487

3.  Tolerance Limits, Self-understanding, and Stress Resilience in Integrative Recovery of Inflammatory Bowel Disease.

Authors:  Kari Skrautvol; Dagfinn Nåden
Journal:  Holist Nurs Pract       Date:  2017 Jan/Feb       Impact factor: 1.000

Review 4.  Preoperative Nutritional Conditioning of Crohn's Patients-Systematic Review of Current Evidence and Practice.

Authors:  Fabian Grass; Basile Pache; David Martin; Dieter Hahnloser; Nicolas Demartines; Martin Hübner
Journal:  Nutrients       Date:  2017-06-01       Impact factor: 5.717

5.  Sarcopenia is associated with poor clinical outcomes in patients with inflammatory bowel disease: a prospective cohort study.

Authors:  Sifan Liu; Xueli Ding; Giuseppe Maggiore; Andrea Pietrobattista; Sanjaya K Satapathy; Zibin Tian; Xue Jing
Journal:  Ann Transl Med       Date:  2022-03

6.  Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn's disease or ulcerative colitis.

Authors:  Gustav Mikkelsen; Børge Lillebo; Arild Faxvaag
Journal:  Pract Lab Med       Date:  2021-04-17

Review 7.  Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases.

Authors:  Alicja Derkacz; Pawel Olczyk; Katarzyna Komosinska-Vassev
Journal:  Dis Markers       Date:  2018-06-11       Impact factor: 3.434

Review 8.  The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.

Authors:  Lifang Liang; Rongxiao Lin; Ying Xie; Huaqing Lin; Fangyuan Shao; Wen Rui; Hongyuan Chen
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.